# Management of obesity in advanced chronic liver disease

## TL;DR

This paper discusses how obesity affects advanced liver disease and explores new treatment options like lifestyle changes, medications, and surgery.

## Contribution

The paper highlights recent anti-obesity medications as new tools for personalized treatment in patients with obesity and liver disease.

## Key findings

- Obesity is increasingly common in patients with advanced chronic liver disease.
- Higher BMI worsens liver disease outcomes regardless of the cause.
- New anti-obesity medications offer promising treatment options alongside lifestyle and surgical interventions.

## Abstract

Obesity has emerged as a major global health challenge and is closely associated with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction- and alcohol-associated liver disease (MetALD). Overall, an increased prevalence of obesity has been reported in patients with advanced chronic liver disease (ACLD), in whom it adversely impacts prognosis. Importantly, increased BMI is recognised as a modifiable risk factor for progression of liver disease, regardless of aetiology. The recent approval of effective and well-tolerated anti-obesity medications offers new opportunities, alongside therapeutic lifestyle changes and bariatric surgery, for the personalised management of patients living with obesity and associated liver disease.

Image 1